title: Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer.
abstract: The use of mutation screening of BRCA1 and BRCA2 genes as a genetic test is still to a certain extent limited and the oncogeneticist may want to use complementary approaches to identify at-risk individuals. In a series of 23 families with at least three breast or ovarian cancer cases, screened for mutations at BRCA1 and BRCA2 and typed for markers at both loci, we investigated the usefulness of marker segregation information at two levels: 1) to what extent can the indirect approach identify the mutation carrier status of screened cases and their first-degree relatives, and 2) in what way does it help to identify the gene implicated in a family in which neither BRCA1 nor BRCA2 mutation has been detected? Using the indirect approach, the carrier status of the screened case could be determined with quasi certainty in three families and with a high probability in eight families. This status could be inferred in unaffected first-degree relatives as almost certain in one family and as highly probable in six families. Fourteen mutations were found concurrently in our series. Among the nine mutation-negative families, we were able to conclude that a BRCA1 mutation most probably segregated in one and that a mutation other than BRCA1 and BRCA2 was probably involved in two families. Our results show that, in small families, little help is to be expected from linkage data and mutation screening is the only way of identifying the origin of a genetic predisposition in a family. Marker segregation information may be useful in some large breast/ovarian cancer families in which no BRCA1 or BRCA2 mutation has been detected.
authors.affiliation: Unité de Recherches en Epidémiologie des Cancers/INSERM U351, Institut Gustave Roussy, Villejuif, France.
authors.forename: L
authors.initials: L
authors.lastname: Essioux
authors.forename: C
authors.initials: C
authors.lastname: Girodet
authors.forename: O
authors.initials: O
authors.lastname: Sinilnikova
authors.forename: S
authors.initials: S
authors.lastname: Pagès
authors.forename: F
authors.initials: F
authors.lastname: Eisinger
authors.forename: S
authors.initials: S
authors.lastname: de Résende
authors.forename: C
authors.initials: C
authors.lastname: Maugard
authors.forename: D
authors.initials: D
authors.lastname: Lanoë
authors.forename: M
authors.initials: M
authors.lastname: Longy
authors.forename: Y J
authors.initials: YJ
authors.lastname: Bignon
authors.forename: H
authors.initials: H
authors.lastname: Sobol
authors.forename: C
authors.initials: C
authors.lastname: Bonaïti-Pellié
authors.forename: D
authors.initials: D
authors.lastname: Stoppa-Lyonnet
mesh_terms: D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein; D014408:Biomarkers, Tumor / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics*; D020090:Chromosome Segregation / Q000235:genetics; D005260:Female; D005817:Genetic Counseling; D008040:Genetic Linkage; D005820:Genetic Testing; D006579:Heterozygote; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics; D010051:Ovarian Neoplasms / Q000235:genetics*; D010375:Pedigree; D014157:Transcription Factors / Q000235:genetics
chemical_list: D019313:BRCA1 Protein; D024682:BRCA2 Protein; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D014157:Transcription Factors